| Primary |
| Cystic Fibrosis |
15.9% |
| Drug Use For Unknown Indication |
14.9% |
| Product Used For Unknown Indication |
14.5% |
| Sepsis |
9.8% |
| Antibiotic Prophylaxis |
9.4% |
| Infection |
4.7% |
| Prophylaxis |
4.3% |
| Analgesia |
3.6% |
| Anti-infective Therapy |
3.3% |
| Endocarditis |
3.3% |
| Induction Of Anaesthesia |
2.5% |
| Pyrexia |
2.2% |
| Endocarditis Staphylococcal |
1.8% |
| Osteitis |
1.8% |
| Urinary Tract Infection |
1.8% |
| Acute Myeloid Leukaemia |
1.4% |
| Conjunctivitis |
1.4% |
| Analgesic Therapy |
1.1% |
| Bacterial Infection |
1.1% |
| Conjunctivitis Infective |
1.1% |
|
| Renal Failure Acute |
38.2% |
| Renal Tubular Necrosis |
10.8% |
| Anaphylactic Reaction |
8.8% |
| Myocardial Infarction |
4.9% |
| Ototoxicity |
2.9% |
| Tubulointerstitial Nephritis |
2.9% |
| Vertigo |
2.9% |
| Vestibular Disorder |
2.9% |
| Vision Blurred |
2.9% |
| Visual Acuity Reduced |
2.9% |
| Abdominal Pain Upper |
2.0% |
| Cellulitis |
2.0% |
| Colitis |
2.0% |
| Deafness |
2.0% |
| Dizziness |
2.0% |
| Gamma-glutamyltransferase Increased |
2.0% |
| Medication Error |
2.0% |
| Myoclonus |
2.0% |
| Neutropenia |
2.0% |
| Renal Failure |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
22.9% |
| Endocarditis |
16.0% |
| Pyrexia |
6.2% |
| Drug Use For Unknown Indication |
6.0% |
| Pneumonia |
4.6% |
| Sepsis |
4.1% |
| Drug Therapy |
3.7% |
| Pain |
3.7% |
| Abdominal Injury |
3.5% |
| Infection |
3.5% |
| Acute Myeloid Leukaemia |
3.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.0% |
| Hypertension |
2.7% |
| Nutritional Support |
2.7% |
| Pneumonia Mycoplasmal |
2.7% |
| Infective Thrombosis |
2.5% |
| Rash |
2.5% |
| Staphylococcal Sepsis |
2.5% |
| Device Related Infection |
2.1% |
| Foetal Exposure Timing Unspecified |
2.0% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
20.0% |
| Renal Failure Acute |
12.5% |
| Clostridial Infection |
7.5% |
| Renal Failure |
6.3% |
| Toxic Epidermal Necrolysis |
6.3% |
| Drug Hypersensitivity |
5.0% |
| Tendonitis |
5.0% |
| Leukocyturia |
3.8% |
| Rash |
3.8% |
| Sepsis Neonatal |
3.8% |
| Vision Blurred |
3.8% |
| Acute Generalised Exanthematous Pustulosis |
2.5% |
| Deafness Unilateral |
2.5% |
| Dizziness |
2.5% |
| Hemiplegia |
2.5% |
| Hepatocellular Injury |
2.5% |
| Hypoaesthesia |
2.5% |
| Hypokalaemia |
2.5% |
| Inner Ear Disorder |
2.5% |
| Megacolon |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
55.1% |
| Drug Use For Unknown Indication |
10.4% |
| Prophylaxis |
8.7% |
| Hypertension |
3.2% |
| Rheumatoid Arthritis |
3.1% |
| Colorectal Cancer |
2.0% |
| Pain |
1.7% |
| Infection Prophylaxis |
1.5% |
| Sepsis |
1.5% |
| Endocarditis |
1.4% |
| Pneumonia |
1.4% |
| Diabetes Mellitus |
1.3% |
| Pulmonary Arterial Hypertension |
1.2% |
| Arteriosclerosis |
1.1% |
| Constipation |
1.1% |
| Infection |
1.1% |
| Nausea |
1.1% |
| Juvenile Arthritis |
1.1% |
| Vomiting |
1.1% |
| Acute Myeloid Leukaemia |
1.0% |
|
| Post Procedural Complication |
10.2% |
| Vomiting |
10.2% |
| Pyrexia |
8.7% |
| Renal Failure Acute |
7.9% |
| White Blood Cell Count Decreased |
7.1% |
| Neonatal Respiratory Distress Syndrome |
4.7% |
| Arthropathy |
3.9% |
| Bone Lesion |
3.9% |
| Interstitial Lung Disease |
3.9% |
| Pneumonia |
3.9% |
| Renal Impairment |
3.9% |
| Thrombocytopenia |
3.9% |
| Urinary Tract Infection |
3.9% |
| Wheezing |
3.9% |
| White Blood Cell Count Abnormal |
3.9% |
| Acute Generalised Exanthematous Pustulosis |
3.1% |
| Cerebral Infarction |
3.1% |
| Diabetes Mellitus |
3.1% |
| Diarrhoea |
3.1% |
| Hyperglycaemia |
3.1% |
|
| Interacting |
|
|
